XSES
1H3
Market cap968kUSD
Sep 17, Last price
0.00SGD
1Q
0.00%
IPO
-99.26%
Name
Clearbridge Health Ltd
Chart & performance
P/E
—
P/S
0.12
EPS
—
Div yield, %
—
Shrs. gr., 5y
40.51%
Rev. gr., 5y
-22.82%
Revenues
10m
+0.26%
Net income
-13m
L+257.76%
CFO
-3m
L+37.62%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2010 and headquartered in Singapore, Clearbridge Health Limited operates as an investment holding company, delivering diverse healthcare solutions globally, including in Singapore, the Philippines, Hong Kong, and Malaysia. The firm's activities are organized into three key divisions: Strategic Investments, Healthcare Systems, and Medical Clinics/Centres. Its extensive range of services encompasses advanced imaging diagnostics, such as general X-ray, CT scans (including dental cone beam), mammography, MRI, and ultrasound. Furthermore, Clearbridge offers general wellness screenings for conditions like diabetes, high blood pressure, and elevated cholesterol, alongside vaccination programs. Specialized care includes renal treatment, clinical services, aesthetic procedures, and dental and orthodontic services. Beyond patient care, the company provides consultancy to healthcare organizations and is involved in the wholesale supply of medicinal and pharmaceutical products.
Key people
Johnson Chen
Non-Independent Non-Executive Chairman of the Board
Jeremy Yee
Chief Executive Officer, Executive Director · since 2017
Fexlicia Lee
Financial Controller · since 2017
Simon Hoo
Chief Business Officer · since 2017
Jonathan Liau
Chief Commercial Officer · since 2017
Company Secretary · since 2019
Andrew Lord
Lead Independent Director · since 2010
Mark Ryan
Independent Director
Non-Executive Independent Director · since 2018
Headquarters & legal address
37 JALAN PEMIMPIN
SINGAPORE, 01 577177
SG
SINGAPORE, 01 577177
SG
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||